PPAR δ activity in cardiovascular diseases: A potential pharmacological target

PPAR Research

Volumn , Issue , 2009, Pages

  Tesse, Angela ^a   Andriantsitohaina, Ramaroson ^a   Ragot, Thierry ^b  

^a UNIVERSITÉ D'ANGERS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; BERAPROST; CARBACYCLIN; CER 002; KD 3010; L 165461; L 796449; MBX 8025; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG INHIBITION; HEART ARRHYTHMIA; HEART FAILURE; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTRIGLYCERIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

EID: 63849216716     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/745821     Document Type: Article

References (83)

1. Escher P., Wahli W., Peroxisome proliferator-activated receptors: insight into multiple cellular functions Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2000 448 2 121 138
2. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
3. Kersten S., Desvergne B., Wahli W., Roles of PPARs in health and disease Nature 2000 405 6785 421 424
4. Barger P. M., Kelly D. P., PPAR signaling in the control of cardiac energy metabolism Trends in Cardiovascular Medicine 2000 10 6 238 245
5. Loichot C., Jesel L., Tesse A., Deletion of peroxisome proliferator-activated receptor- induces an alteration of cardiac functions American Journal of Physiology 2006 291 1 H161 H166
6. Son N.-H., Park T.-S., Yamashita H., Cardiomyocyte expression of PPAR leads to cardiac dysfunction in mice The Journal of Clinical Investigation 2007 117 10 2791 2801
7. Inoue H., Tanabe T., Umesono K., Feedback control of cyclooxygenase-2 expression through PPAR The Journal of Biological Chemistry 2000 275 36 28028 28032
8. Maggi L. B. Jr., Sadeghi H., Weigand C., Scarim A. L., Heitmeier M. R., Corbett J. A., Anti-inflammatory actions of 15-deoxy- 12, 14 -prostaglandin J 2 and troglitazone evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression Diabetes 2000 49 3 346 355
9. Mohanty P., Aljada A., Ghanim H., Evidence for a potent antiinflammatory effect of rosiglitazone The Journal of Clinical Endocrinology Metabolism 2004 89 6 2728 2735
10. Marfella R., DAmico M., Esposito K., The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment Diabetes 2006 55 3 622 632
11. Hinz B., Brune K., Pahl A., 15-deoxy- 12, 14 -prostaglandin J 2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR- -independent mechanism Biochemical and Biophysical Research Communications 2003 302 2 415 420
12. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., Hiwada K., Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells European Journal of Pharmacology 2000 407 3 227 235
13. Tesse A., Al-Massarani G., Wangensteen R., Reitenbach S., Martnez M. C., Andriantsitohaina R., Rosiglitazone, a peroxisome proliferator-activated receptor- agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins The Journal of Pharmacology and Experimental Therapeutics 2008 324 2 539 547
14. Kliewer S. A., Forman B. M., Blumberg B., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359
15. Mukherjee R., Jow L., Croston G. E., Paterniti J. R. Jr., Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR 2 versus PPAR 1 and activation with retinoid X receptor agonists and antagonists The Journal of Biological Chemistry 1997 272 12 8071 8076
16. Gupta R. A., Tan J., Krause W. F., Prostacyclin-mediated activation of peroxisome proliferator-activated receptor in colorectal cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 24 13275 13280
17. Pola R., Gaetani E., Flex A., Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors Journal of Molecular and Cellular Cardiology 2004 36 3 363 370
18. Moraes L. A., Piqueras L., Bishop-Bailey D., Peroxisome proliferator-activated receptors and inflammation Pharmacology and Therapeutics 2006 110 3 371 385
19. Piqueras L., Reynolds A. R., Hodivala-Dilke K. M., Activation of PPAR / induces endothelial cell proliferation and angiogenesis Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1 63 69
20. Fukumoto K., Yano Y., Virgona N., Peroxisome proliferator-activated receptor as a molecular target to regulate lung cancer cell growth FEBS Letters 2005 579 17 3829 3836
21. Stephen R. L., Gustafsson M. C. U., Jarvis M., Activation of peroxisome proliferator-activated receptor stimulates the proliferation of human breast and prostate cancer cell lines Cancer Research 2004 64 9 3162 3170
22. Burkart E. M., Sambandam N., Han X., Nuclear receptors PPAR / and PPAR direct distinct metabolic regulatory programs in the mouse heart The Journal of Clinical Investigation 2007 117 12 3930 3939
23. Planavila A., Laguna J. C., Vzquez-Carrera M., Nuclear factor- B activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy The Journal of Biological Chemistry 2005 280 17 17464 17471
24. Forman B. M., Chen J., Evans R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4312 4317
25. Falcetti E., Flavell D. M., Staels B., Tinker A., Haworth S. G., Clapp L. H., IP receptor-dependent activation of PPAR by stable prostacyclin analogues Biochemical and Biophysical Research Communications 2007 360 4 821 827
26. Sznaidman M. L., Haffner C. D., Maloney P. R., Novel selective small molecule agonists for peroxisome proliferator-activated receptor (PPAR )-synthesis and biological activity Bioorganic Medicinal Chemistry Letters 2003 13 9 1517 1521
27. Berger J., Leibowitz M. D., Doebber T. W., Novel peroxisome proliferator-activated receptor (PPAR) and PPAR ligands produce distinct biological effects The Journal of Biological Chemistry 1999 274 10 6718 6725
28. Kang K., Hatano B., Lee C.-H., PPAR agonists and metabolic diseases Current Atherosclerosis Reports 2007 9 1 72 77
29. Rittenhouse P. A., Dyslipidemia rescue BioCentury, The Bernstein Report on BioBusiness 2008 A12 A13
30. Liou J.-Y., Lee S., Ghelani D., Matijevic-Aleksic N., Wu K. K., Protection of endothelial survival by peroxisome proliferator-activated receptor- mediated 14-3-3 upregulation Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 7 1481 1487
31. He T.-C., Chan T. A., Vogelstein B., Kinzler K. W., PPAR is an APC-regulated target of nonsteroidal anti-inflammatory drugs Cell 1999 99 3 335 345
32. Tan N. S., Michalik L., Noy N., Critical roles of PPAR / in keratinocyte response to inflammation Genes Development 2001 15 24 3263 3277
33. Hao C.-M., Redha R., Morrow J., Breyer M. D., Peroxisome proliferator-activated receptor activation promotes cell survival following hypertonic stress The Journal of Biological Chemistry 2002 277 24 21341 21345
34. Brunelli L., Cieslik K. A., Alcorn J. L., Vatta M., Baldini A., Peroxisome proliferator-activated receptor- upregulates 14-3-3 in human endothelial cells via CCAAT/enhancer binding protein- Circulation Research 2007 100 5 e59 e71
35. Pesant M., Sueur S., Dutartre P., Peroxisome proliferator-activated receptor (PPAR ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis Cardiovascular Research 2006 69 2 440 449
36. Yue T.-L., Nerurkar S. S., Bao W., In vivo activation of peroxisome proliferator-activated receptor- protects the heart from ischemia/reperfusion injury in Zucker fatty rats The Journal of Pharmacology and Experimental Therapeutics 2008 325 2 466 474
37. Teunissen B. E. J., Smeets P. J. H., Willemsen P. H. M., De Windt L. J., Van der Vusse G. J., Van Bilsen M., Activation of PPAR inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts Cardiovascular Research 2007 75 3 519 529
38. Lin H., Lee J.-L., Hou H.-H., Chung C.-P., Hsu S.-P., Juan S.-H., Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells Journal of Cellular Physiology 2008 214 2 434 441
39. Yang L., Zhou Z.-G., Zheng X.-L., RNA interference against peroxisome proliferator-activated receptor gene promotes proliferation of human colorectal cancer cells Diseases of the Colon and Rectum 2008 51 3 318 328
40. Zeng L., Geng Y., Tretiakova M., Yu X., Sicinski P., Kroll T. G., Peroxisome proliferator-activated receptor- induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors Cancer Research 2008 68 16 6578 6586
41. Liang P., Jiang B., Yang X., The role of peroxisome proliferator- activated receptor- / in epidermal growth factor-induced HaCaT cell proliferation Experimental Cell Research 2008 314 17 3142 3151
42. Michalik L., Desvergne B., Tan N. S., Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) and PPAR mutant mice Journal of Cell Biology 2001 154 4 799 814
43. Semenza G. L., Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling Journal of Cellular Biochemistry 2007 102 4 840 847
44. Han J. K., Lee H. S., Yang H. M., Peroxisome proliferator-activated receptor- agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway Circulation 2008 118 10 1021 1033
45. Hur J., Yoon C.-H., Lee C.-S., Akt is a key modulator of endothelial progenitor cell trafficking in ischemic muscle Stem Cells 2007 25 7 1769 1778
46. Dimmeler S., Aicher A., Vasa M., HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway The Journal of Clinical Investigation 2001 108 3 391 397
47. Llevadot J., Murasawa S., Kureishi Y., HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells The Journal of Clinical Investigation 2001 108 3 399 405
48. He T., Lu T., dUscio L. V., Lam C. F., Lee H. C., Katusic Z. S., Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells Circulation Research 2008 103 1 80 88
49. Mller-Brsselbach S., Kmhoff M., Rieck M., Deregulation of tumor angiogenesis and blockade of tumor growth in PPAR -deficient mice The EMBO Journal 2007 26 15 3686 3698
50. Graham T. L., Mookherjee C., Suckling K. E., Palmer C. N. A., Patel L., The PPAR agonist GW0742X reduces atherosclerosis in LDLR-/-mice Atherosclerosis 2005 181 1 29 37
51. Li A. C., Binder C. J., Gutierrez A., Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR, /, and The Journal of Clinical Investigation 2004 114 11 1564 1576
52. Takata Y., Liu J., Yin F., PPAR -mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4277 4282
53. Barish G. D., Atkins A. R., Downes M., PPAR regulates multiple proinflammatory pathways to suppress atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4271 4276
54. Oliver W. R. Jr., Shenk J. L., Snaith M. R., A selective peroxisome proliferator-activated receptor agonist promotes reverse cholesterol transport Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311
55. Dimmeler S., Haendeler J., Zeiher A. M., Regulation of endothelial cell apoptosis in atherothrombosis Current Opinion in Lipidology 2002 13 5 531 536
56. Lee C.-H., Chawla A., Urbiztondo N., Liao D., Boisvert W. A., Evans R. M., Transcriptional repression of atherogenic inflammation: modulation by PPAR Science 2003 302 5644 453 457
57. Tanaka T., Yamamoto J., Iwasaki S., Activation of peroxisome proliferator-activated receptor induces fatty acid -oxidation in skeletal muscle and attenuates metabolic syndrome Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15924 15929
58. Wang Y.-X., Lee C.-H., Tiep S., Peroxisome-proliferator-activated receptor activates fat metabolism to prevent obesity Cell 2003 113 2 159 170
59. Liu Y., Yin G., Surapisitchat J., Berk B. C., Min W., Laminar flow inhibits TNF-induced ASK1 activation by preventing dissociation of ASK1 from its inhibitor 14-3-3 The Journal of Clinical Investigation 2001 107 7 917 923
60. Zhang S., Ren J., Zhang C. E., Treskov I., Wang Y., Muslin A. J., Role of 14-3-3-mediated p38 mitogen-activated protein kinase inhibition in cardiac myocyte survival Circulation Research 2003 93 11 1026 1028
61. Kagan A., Melman Y. F., Krumerman A., McDonald T. V., 14-3-3 amplifies and prolongs adrenergic stimulation of HERG K + channel activity The EMBO Journal 2002 21 8 1889 1898
62. Choe C.-U., Schulze-Bahr E., Neu A., C-terminal HERG (LQT2) mutations disrupt I Kr channel regulation through 14-3-3 Human Molecular Genetics 2006 15 19 2888 2902
63. Allouis M., Le Bouffant F., Wilders R., 14-3-3 is a regulator of the cardiac voltage-gated sodium channel Nav1.5 Circulation Research 2006 98 12 1538 1546
64. Fan Y., Wang Y., Tang Z., Suppression of pro-inflammatory adhesion molecules by PPAR- in human vascular endothelial cells Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 2 315 321
65. Cheng L., Ding G., Qin Q., Cardiomyocyte-restricted peroxisome proliferator-activated receptor- deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy Nature Medicine 2004 10 11 1245 1250
66. Frangogiannis N. G., Smith C. W., Entman M. L., The inflammatory response in myocardial infarction Cardiovascular Research 2002 53 1 31 47
67. Wilson P. W. F., DAgostino R. B., Parise H., Sullivan L., Meigs J. B., Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus Circulation 2005 112 20 3066 3072
68. Miettinen H., Lehto S., Salomaa V., Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group Diabetes Care 1998 21 1 69 75
69. Kostin S., Hein S., Arnon E., Scholz D., Schaper J., The cytoskeleton and related proteins in the human failing heart Heart Failure Reviews 2000 5 3 271 280
70. Weber K. T., Are myocardial fibrosis and diastolic dysfunction reversible in hypertensive heart disease? Congestive Heart Failure 2005 11 6 322 326
71. Petrov V. V., Fagard R. H., Lijnen P. J., Stimulation of collagen production by transforming growth factor- 1 during differentiation of cardiac fibroblasts to myofibroblasts Hypertension 2002 39 2 258 263
72. Tomasek J. J., Gabbiani G., Hinz B., Chaponnier C., Brown R. A., Myofibroblasts and mechano-regulation of connective tissue remodelling Nature Reviews Molecular Cell Biology 2002 3 5 349 363
73. Eghbali M., Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation Basic Research in Cardiology 1992 87 supplement 2 183 189
74. Zhang H., Pi R., Li R., PPAR / activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts Archives of Biochemistry and Biophysics 2007 460 1 25 32
75. Makinde A.-O., Kantor P. F., Lopaschuk G. D., Maturation of fatty acid and carbohydrate metabolism in the newborn heart Molecular and Cellular Biochemistry 1998 188 1-2 49 56
76. Sack M. N., Rader T. A., Park S., Bastin J., McCune S. A., Kelly D. P., Fatty acid oxidation enzyme gene expression is downregulated in the failing heart Circulation 1996 94 11 2837 2842
77. Planavila A., Rodrguez-Calvo R., Jov M., Peroxisome proliferator- activated receptor / activation inhibits hypertrophy in neonatal rat cardiomyocytes Cardiovascular Research 2005 65 4 832 841
78. Barish G. D., Narkar V. A., Evans R. M., PPAR : a dagger in the heart of the metabolic syndrome The Journal of Clinical Investigation 2006 116 3 590 597
79. Grimaldi P. A., Regulatory role of peroxisome proliferator-activated receptor delta (PPAR ) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie 2005 87 1 5 8
80. Lee C.-H., Olson P., Hevener A., PPAR regulates glucose metabolism and insulin sensitivity Proceedings of the National Academy of Sciences of the United States of America 2006 103 9 3444 3449
81. Wallace J. M., Schwarz M., Coward P., Effects of peroxisome proliferator-activated receptor / agonists on HDL-cholesterol in vervet monkeys Journal of Lipid Research 2005 46 5 1009 1016
82. Sprecher D. L., Massien C., Pearce G., Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor agonist Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 359 365
83. Lin H., Lin T.-N., Cheung W.-M., Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction Circulation 2002 105 16 1962 1969